location： Home > Products > Signaling Pathways > Metabolism > Carbonic Anhydrase

Brinzolamide

Price：

Market Price：

This product is for research use only, not for human use. We do not sell to patients.

Number： - + Pieces（InventoryPieces）

InvivoChem Cat #: V0898

CAS #: 138890-62-7Purity ≥98%

Description: Brinzolamide (AL-4862; AL4862; Azopt, Alcon Laboratories, Befardin, AL4862) is a highly potent and selective CAI (carbonic anhydrase II inhibitor) with anti-hypertensive activity. It inhibits carbonic anhydrase II with an IC50 of 3.19 nM. Brinzolamide is used to treat glaucoma (open angle-type) or other eye diseases (e.g. ocular hypertension).

References: Surv Ophthalmol. 2000 Jan;44 Suppl 2:S119-29; Ophthalmol. 2000 Jan;44 Suppl 2:S147-53.

Customer Validation

Top Publications Citing Invivochem Products

详情页公告 Product Catalog 2022

Bulletin Board

详情页公告 Guide to Product Handling

Publications Citing InvivoChem Products

Physicochemical and Storage Information
Protocol
Quality Control Documentation
Related Biological Data
Customer Review

Molecular Weight (MW)	383.51
Formula	C12H21N3O5S3
CAS No.	138890-62-7
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 77 mg/mL (200.8 mM)
	Water: < 1 mg/mL
	Ethanol: < 1 mg/mL
SMILES	O=S(C(S1)=CC2=C1S(N(CCCOC)C[[email protected]@H]2NCC)(=O)=O)(N)=O
Synonyms	AL 4862; Brinzolamide; trade names Azopt, Alcon Laboratories, Befardin, Fardi Medicals; AL-4862; AL4862

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
- Mass
- Concentration
- Volume
- Molecular Weight *
- =
- ×
- ×
The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂
- Concentration _(start)
- ×
- Volume _(start)
- =
- Concentration _(final)
- ×
- Volume _(final)
- ×
- =
- ×
- C1
- V1
- C2
- V2

In Vitro	In vitro activity: Brinzolamide is the newest topical CAI to be successfully developed and marketed. It is a safe and efficacious glaucoma drug. In the in vitro assay, brinzolamide has its highest affinity (Ki of 0.13nM) and inhibitory potency (IC50 of 3.19 nM) for CA-II. It has much higher affinity and greater potency for CA-II than for CA-I and CAIV. In the in vivo models, administration of brinzolamide significantly reduces the intraocular pressure (IOP) both in the pigmented rabbits and cynomolgus monkeys with ocular hypertension induced by argon laser trabeculoplasty. Kinase Assay: Brinzolamide(AL 4862) is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM.
In Vivo	Brinzolamide (< 1 mg) ophthalmic suspension lowers intraocular pressure in Dutch-belted pigmented rabbits in a dose-dependent manner with an onset within 0.5 hour and a peak response by 1–2 hours. Brinzolamide (0.6 mg) ophthalmic suspension lowers intraocular pressure in laser-treated glaucomatous cynomolgus monkeys in a dose-dependent manner with an onset within 1 hour and a peak response by 3 hours. Brinzolamide dosages of 30 mg/kg, produces a 44% reduction in intestinal charcoal meal progression, but 1 and 10 mg/kg produced 8% and 18% decreases, respectively, in male CD-1 mice. Brinzolamide of 1 mg/kg, 10 mg/kg, and 30 mg/kg prolongs barbiturate sleep time by 57%, 15%, and 35%, respectively, in male CD-1 mice. Brinzolamide (< 3%) produces significantly greater mean percent intraocular pressure reductions and mean intraocular pressure reductions compared with placebo in patients with primary, open-angle glaucoma or ocular hypertension. The optimal intraocular pressure-lowering concentration of brinzolamide is 1%, brinzolamide 1% is well tolerated by patients with primary open-angle glaucoma or ocular hypertension when administered twice daily. Brinzolamide significantly decreases intraocular pressure and arteriovenous passage time compared with placebo in healthy volunteers. Brinzolamide (2%) increases optic nerve head blood flow and decreases intraocular pressure in tranquilized Dutch-belted rabbits. Brinzolamide (1%) reduces intraocular pressure by reducing aqueous flow and not by affecting aqueous humor drainage in normotensive eyes of rabbits and hypertensive eyes of monkeys.
Animal model	Mice
Formulation & Dosage	1 mg/kg, 10 mg/kg, and 30 mg/kg
References	Surv Ophthalmol. 2000 Jan;44 Suppl 2:S119-29; Surv Ophthalmol. 2000 Jan;44 Suppl 2:S147-53.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Purity ≥98%
COA
MSDS
NMR

Changes in IOP over 24 hours after brinzolamide administration. (a) Brinzolamide-treated eye. (b) Brinzolamide-untreated eye. Open Ophthalmol J. 2008; 2: 160–164.	Percent reduction in IOPs over 24 hours after brinzolamide administration. Open Ophthalmol J. 2008; 2: 160–164.	Difference in IOP between right and left eyes before and after brinzolamide administration. Open Ophthalmol J. 2008; 2: 160–164.

Home Prev Next Last page / pices

发评论

Your information is safe with us. * Required Fields.

Product name

Cat

Applicant name

Email address

Phone number

Organization name

Country

Requested quantity

Remarks